[Influence of specific osteoporosis drugs on fracture healing].
Einfluss spezifischer Osteoporosemedikamente auf die Frakturheilung.
Bisphosphonates
Bone metabolism
Denosumab
Sclerostin
Teriparatid
Journal
Der Unfallchirurg
ISSN: 1433-044X
Titre abrégé: Unfallchirurg
Pays: Germany
ID NLM: 8502736
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
pubmed:
28
5
2019
medline:
21
9
2019
entrez:
25
5
2019
Statut:
ppublish
Résumé
For the treatment of disturbed fracture healing, drugs could be given in addition to surgical procedures. Specific osteoporosis drugs affect the bone metabolism and are used to treat osteoporosis, particularly after a fragility fracture has occurred. Therefore, their use would be conceivable to improve a disturbed fracture healing. This article presents the available and upcoming specific osteoporosis drugs and investigates whether these substances affect fracture healing in the context of osteoporosis. Furthermore, it is discussed whether disturbed fracture healing can be improved by the use of these substances. A literature search (PubMed) was conducted using key terms. Preclinical studies, clinical studies, reviews and meta-analyses were considered in order to present the current knowledge in a clinically relevant context. Preclinical and clinical studies show that specific osteoporosis drugs have no relevant negative impact on the healing of fragility fractures. A tendency to improve a disturbed fracture healing was attributed to bone anabolic substances; however, studies are inconsistent and there is no approval for this application. Following a fragility fracture, osteoporosis should be diagnosed according to the guidelines and, if necessary, treated with specific osteoporosis drugs, since in principle they do not impair fracture healing but significantly reduce the risk of subsequent fractures. Approval to improve fracture healing requires further investigations.
Sections du résumé
BACKGROUND
BACKGROUND
For the treatment of disturbed fracture healing, drugs could be given in addition to surgical procedures. Specific osteoporosis drugs affect the bone metabolism and are used to treat osteoporosis, particularly after a fragility fracture has occurred. Therefore, their use would be conceivable to improve a disturbed fracture healing.
OBJECTIVE
OBJECTIVE
This article presents the available and upcoming specific osteoporosis drugs and investigates whether these substances affect fracture healing in the context of osteoporosis. Furthermore, it is discussed whether disturbed fracture healing can be improved by the use of these substances.
MATERIAL AND METHODS
METHODS
A literature search (PubMed) was conducted using key terms. Preclinical studies, clinical studies, reviews and meta-analyses were considered in order to present the current knowledge in a clinically relevant context.
RESULTS
RESULTS
Preclinical and clinical studies show that specific osteoporosis drugs have no relevant negative impact on the healing of fragility fractures. A tendency to improve a disturbed fracture healing was attributed to bone anabolic substances; however, studies are inconsistent and there is no approval for this application.
CONCLUSION
CONCLUSIONS
Following a fragility fracture, osteoporosis should be diagnosed according to the guidelines and, if necessary, treated with specific osteoporosis drugs, since in principle they do not impair fracture healing but significantly reduce the risk of subsequent fractures. Approval to improve fracture healing requires further investigations.
Identifiants
pubmed: 31123799
doi: 10.1007/s00113-019-0669-x
pii: 10.1007/s00113-019-0669-x
doi:
Substances chimiques
Bone Density Conservation Agents
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
506-511Références
Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55
pubmed: 10080918
J Biol Chem. 2005 May 20;280(20):19883-7
pubmed: 15778503
Spine (Phila Pa 1976). 2009 Jan 15;34(2):121-30
pubmed: 19112335
J Bone Miner Res. 2010 Feb;25(2):404-14
pubmed: 19594305
J Bone Joint Surg Br. 2011 Jan;93(1):131-9
pubmed: 21196558
J Clin Endocrinol Metab. 2012 Feb;97(2):311-25
pubmed: 22238383
Calcif Tissue Int. 2012 May;90(5):343-53
pubmed: 22451221
J Bone Joint Surg Am. 2012 Dec 5;94(23):2113-9
pubmed: 23097066
Nat Rev Rheumatol. 2015 Jan;11(1):45-54
pubmed: 25266456
Osteoporos Int. 2015 Feb;26(2):431-41
pubmed: 25266485
Int Immunopharmacol. 2015 Jan;24(1):7-13
pubmed: 25479724
Osteoporos Int. 2015 Apr;26(4):1251-60
pubmed: 25572046
Bone. 2016 Jan;82:122-34
pubmed: 25952969
Calcif Tissue Int. 2016 Mar;98(3):263-74
pubmed: 26603303
J Bone Metab. 2015 Nov;22(4):175-81
pubmed: 26713308
Injury. 2016 Jan;47 Suppl 1:S65-8
pubmed: 26768295
N Engl J Med. 2016 Jan 21;374(3):254-62
pubmed: 26789873
World J Orthop. 2016 Mar 18;7(3):171-81
pubmed: 27004165
Biomed Res Int. 2016;2016:6040379
pubmed: 27429980
N Engl J Med. 2016 Oct 20;375(16):1532-1543
pubmed: 27641143
PLoS One. 2016 Dec 20;11(12):e0168691
pubmed: 27997614
J Bone Metab. 2017 Feb;24(1):65-73
pubmed: 28326303
BMC Musculoskelet Disord. 2017 Apr 7;18(1):148
pubmed: 28388910
Calcif Tissue Int. 2017 Aug;101(2):217-228
pubmed: 28391431
Medicine (Baltimore). 2017 Apr;96(16):e6571
pubmed: 28422848
N Engl J Med. 2017 Oct 12;377(15):1417-1427
pubmed: 28892457
J Surg Res. 2017 Dec;220:327-335
pubmed: 29180199
Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):173-178
pubmed: 29263728
Osteoporos Int. 2018 May;29(5):1009-1022
pubmed: 29627891
J Bone Miner Res. 2018 Sep;33(9):1686-1697
pubmed: 29694687
Injury. 2018 Aug;49(8):1461-1465
pubmed: 29709376
J Orthop Res. 2018 Oct;36(10):2586-2594
pubmed: 29926970
Int J Oral Maxillofac Implants. 2018 Sep/Oct;33(5):1003-1010
pubmed: 30231085
Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062
pubmed: 30650219
J Intern Med. 2019 Apr;285(4):381-394
pubmed: 30657216